Navigation Links
NICE Gives the Final ‘NO’ to Roche’s Tarcva

NICE (National Institute of Health and Clinical Excellence) has given the ‘thumbs down’ signal to Roche's once-a-day lung cancer// pill Tarceva as its final decision on the matter. It says that the drug is of limited use and too expensive to be given on the NHS.

This decision will only flame the fires of controversy over access to expensive modern cancer treatments, as it follows bickering over whether Herceptin, another Roche product, should be given to women with early breast cancer.

Calling the action as ‘perverse’ and ‘flawed’ Roche is claiming a soon- to -be -followed appeal against NICE’s decision.

Charities have also appealed against the decision that will make needy patients opting for this drug to pay for them, out of their own pockets.

Mike Unger, chief executive of The Roy Castle Lung Cancer Foundation, says: "We are obviously severely disappointed and disillusioned with NICE’s decision not to approve Tarceva purely on economic grounds.

“It's the second blow that NICE has dealt to lung cancer patients in a month, following the announcement to decline Alimta - so there are now very few options left for lung cancer patients.”

NICE ‘s Chief Executive Andrew Dillon has come out against Roche saying that data has revealed that prescribing Tarceva is not an effective use of National Health Service resources when compared with using either Sanofi-Aventis' Taxotere or best supportive care.

Still Dillon has conceded that evidence on the drug is still emerging and has called for more research to test if certain sub- groups would benefit from the drug.

In defense, Roche says clinical trials have shown that Tarceva reduced symptoms of non-small-cell lung cancer, the most common type of the disease, and increased one-year survival rates by 41 percent.

Tarceva was licensed and launched in Britain in 2005 at a cost of 1,631 pounds for one month's treatment.

The medicine belongs to a new generation of "smart drugs", or targeted therapies, which attack only cancer cells and are tolerated much better than traditional chemotherapy.

Their high cost, however, stands in the way of its continued use, as governments and insurers around the world are already struggling to contain rising healthcare costs.


Related medicine news :

1. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
2. Gene Therapy Gives Hope For Patients With Muscular Dystrophy
3. Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients
4. US Doctors Association Gives away $110,000 To NGO’
5. Woman In Coma Gives Birth To Daughter
6. Artificial Heart , Gives Hope For Patients Awaiting a Heart Transplant
7. New Eye Surgery Gives Hope To Short-Sighted
8. Jharkhand Gives Health industry status
9. WHO Gives Its Approval For Bird Flu Test Kit
10. FDA Gives Its Approval For Inhaler
11. Congestion for Use of Clarinex-D 12 Hour cleared – FDA Gives the No
Post Your Comments:

(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
(Date:6/23/2016)... 23, 2016 Revolutionary technology includes ... Oticon , industry leaders in advanced audiology and hearing ... Oticon Opn ™, the world,s first internet connected hearing ... IoT devices.      (Photo: ... number of ,world firsts,: , TwinLink™ - ...
Breaking Medicine Technology: